We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
SOURCE Antengene Corporation Limited
https://rt.newswire.ca/rt.gif?NewsItemId=AE35949&Transmission_Id=202507272352PR_NEWS_ASPR_____AE35949A&DateId=20250727